Key result
Cardiac CT provides critical diagnostic and prognostic utility for coronary and structural disease in cardio-oncology.
Why the study?
Limited guidelines and questions remain regarding optimal screening, imaging modality choice, and management strategies in aging cancer survivors and patients undergoing certain chemotherapies.
Cardiac CT, including CAC scoring and CCTA, is a valuable non-invasive imaging modality for pre-treatment cardiovascular risk stratification, diagnosis of acute complications, and long-term surveillance in the cardio-oncology population.
Opinion statementThe increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.
No takes yet. Share an insight, caveat, or question.
Layoun et al. (2019) conducted a review in Cardio-oncology (cancer survivors and patients undergoing cardiotoxic treatments). Cardiac Computed Tomography (CT) was evaluated. Cardiac computed tomography provides valuable diagnostic and prognostic information for evaluating cardiovascular risk, coronary artery disease, and structural heart complications in the cardio-oncology population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: